Erlotinib: Clinical Trials

4 completed, 1 suspended, 1 terminated, 1 unknown. 7 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	7	Completed 4, Suspended 1, Terminated 1, Unknown 1

Follow Erlotinib: new trials by email Literature Review of Erlotinib trials Research Report on Erlotinib

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients. Pemetrexed, Erlotinib - Carcinoma, Non-Small-Cell Lung	Phase 4	Terminated	Hikma Pharmaceuticals LLC	9	2018-02-28	2020-03-05
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Erlotinib, Chemotherapy - Carcinoma, Non-Small-Cell Lung	Phase 4	Completed	Hoffmann-La Roche	45	2014-01-01	2016-01-13
Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Erlotinib, Gefitinib, Icotinib - Non-Small-Cell Lung Cancer	Phase 4	Unknown	Qilu Hospital of Shandong University	250	2014-01-01	2016-03-29
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Sunitinib, Erlotinib, Midazolam - Non Small-cell Lung Cancer, Renal-cell Cancer	Phase 4	Completed	Markus Joerger	54	2012-01-01	2016-02-02
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Erlotinib - Non-Small Cell Lung Cancer	Phase 4	Completed	Hoffmann-La Roche	51	2011-03-01	2015-03-30
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer Erlotinib - Non-small Cell Lung Cancer Metastatic	Phase 4	Suspended	National Guard Health Affairs	100	2009-10-01	2016-05-13
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Erlotinib - Non-Small Cell Lung Cancer	Phase 4	Completed	Hoffmann-La Roche	6586	2004-11-01	2016-10-05

Conditions studied

Carcinoma, Non-Small-Cell Lung (6)  ·  Lung Neoplasms (2)  ·  Carcinoma, Renal Cell (1)  ·  Gastrointestinal Stromal Tumors (1)

Sponsors

Hoffmann-La Roche (3)  ·  Hikma Pharmaceuticals LLC (1)  ·  Markus Joerger (1)  ·  National Guard Health Affairs (1)  ·  Qilu Hospital of Shandong University (1)

Countries

China (3)  ·  India (2)  ·  Saudi Arabia (2)  ·  Switzerland (2)  ·  Albania (1)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Bosnia and Herzegovina (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Chile (1)  ·  Colombia (1)  ·  Croatia (1)

Top investigators

Abdulrahman Jazieh, MD/MPH (1)  ·  Markus Joerger, MD PhD (1)  ·  Yu Li, Professor (1)

Results publications

PMID 21439671, PMID 25855621, PMID 31200823

NIH funding

2004 (1)